FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2850035306> ?p ?o ?g. }

• W2850035306 endingPage "3535" @default.
• W2850035306 startingPage "3528" @default.
• W2850035306 abstract "BACKGROUND Partial prostate treatment has emerged as a potential method for treating patients with favorable‐risk prostate cancer while minimizing toxicity. The authors previously demonstrated poor rates of biochemical disease control for patients with National Comprehensive Cancer Network (NCCN) intermediate‐risk disease using partial gland treatment with brachytherapy. The objective of the current study was to estimate the rates of distant metastasis and prostate cancer‐specific mortality (PCSM) for this cohort. METHODS Between 1997 and 2007, a total of 354 men with clinical T1c disease, a prostate‐specific antigen (PSA) level < 15 ng/mL, and Gleason grade ≤3 + 4 prostate cancer underwent partial prostate treatment with brachytherapy to the peripheral zone under 0.5‐Tesla magnetic resonance guidance. The cumulative incidences of metastasis and PCSM for the NCCN very low‐risk, low‐risk, and intermediate‐risk groups were estimated. Fine and Gray competing risk regression was used to evaluate clinical factors associated with time to metastasis. RESULTS A total of 22 patients developed metastases at a median of 11.0 years (interquartile range, 6.9‐13.9 years). The 12‐year metastasis rates for patients with very low‐risk, low‐risk, and intermediate‐risk disease were 0.8% (95% confidence interval [95% CI], 0.1%‐4.4%), 8.7% (95% CI, 3.4%‐17.2%), and 15.7% (95% CI, 5.7%‐30.2%), respectively, and the 12‐year PCSM estimates were 1.6% (95% CI, 0.1%‐7.6%), 1.4% (95% CI, 0.1%‐6.8%), and 8.2% (95% CI, 1.9%‐20.7%), respectively. On multivariate analysis, NCCN risk category (low risk: hazard ratio, 6.34 [95% CI, 1.18‐34.06; P = .03] and intermediate risk: hazard ratio, 6.98 [95% CI, 1.23‐39.73; P = .03]) was found to be significantly associated with the time to metastasis. CONCLUSIONS Partial prostate treatment with brachytherapy may be associated with higher rates of distant metastasis and PCSM for patients with intermediate‐risk disease after long‐term follow‐up. Treatment of less than the full gland may not be appropriate for this cohort." @default.
• W2850035306 created "2018-07-19" @default.
• W2850035306 creator A5015096941 @default.
• W2850035306 creator A5018558600 @default.
• W2850035306 creator A5026425735 @default.
• W2850035306 creator A5034131964 @default.
• W2850035306 creator A5040900375 @default.
• W2850035306 creator A5051162180 @default.
• W2850035306 creator A5072365761 @default.
• W2850035306 creator A5074518172 @default.
• W2850035306 creator A5077887056 @default.
• W2850035306 creator A5088554776 @default.
• W2850035306 date "2018-07-05" @default.
• W2850035306 modified "2023-10-15" @default.
• W2850035306 title "Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer" @default.
• W2850035306 cites W1489601213 @default.
• W2850035306 cites W1649499304 @default.
• W2850035306 cites W1827911007 @default.
• W2850035306 cites W1975487888 @default.
• W2850035306 cites W1981103385 @default.
• W2850035306 cites W1987213359 @default.
• W2850035306 cites W1997394967 @default.
• W2850035306 cites W2015114518 @default.
• W2850035306 cites W2026118965 @default.
• W2850035306 cites W2037863833 @default.
• W2850035306 cites W2040103703 @default.
• W2850035306 cites W2049386837 @default.
• W2850035306 cites W2055178611 @default.
• W2850035306 cites W2082328647 @default.
• W2850035306 cites W2093867637 @default.
• W2850035306 cites W2097325625 @default.
• W2850035306 cites W2106869018 @default.
• W2850035306 cites W2112870348 @default.
• W2850035306 cites W2114491648 @default.
• W2850035306 cites W2116116794 @default.
• W2850035306 cites W2131565955 @default.
• W2850035306 cites W2139136818 @default.
• W2850035306 cites W2140583819 @default.
• W2850035306 cites W2143962930 @default.
• W2850035306 cites W2148497849 @default.
• W2850035306 cites W2291306826 @default.
• W2850035306 cites W2510720854 @default.
• W2850035306 cites W2523396458 @default.
• W2850035306 cites W2561352787 @default.
• W2850035306 cites W2577453388 @default.
• W2850035306 cites W2593065207 @default.
• W2850035306 cites W2625400141 @default.
• W2850035306 cites W4375819013 @default.
• W2850035306 doi "https://doi.org/10.1002/cncr.31568" @default.
• W2850035306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6191340" @default.
• W2850035306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29975404" @default.
• W2850035306 hasPublicationYear "2018" @default.
• W2850035306 type Work @default.
• W2850035306 sameAs 2850035306 @default.
• W2850035306 citedByCount "11" @default.
• W2850035306 countsByYear W28500353062019 @default.
• W2850035306 countsByYear W28500353062020 @default.
• W2850035306 countsByYear W28500353062021 @default.
• W2850035306 countsByYear W28500353062022 @default.
• W2850035306 crossrefType "journal-article" @default.
• W2850035306 hasAuthorship W2850035306A5015096941 @default.
• W2850035306 hasAuthorship W2850035306A5018558600 @default.
• W2850035306 hasAuthorship W2850035306A5026425735 @default.
• W2850035306 hasAuthorship W2850035306A5034131964 @default.
• W2850035306 hasAuthorship W2850035306A5040900375 @default.
• W2850035306 hasAuthorship W2850035306A5051162180 @default.
• W2850035306 hasAuthorship W2850035306A5072365761 @default.
• W2850035306 hasAuthorship W2850035306A5074518172 @default.
• W2850035306 hasAuthorship W2850035306A5077887056 @default.
• W2850035306 hasAuthorship W2850035306A5088554776 @default.
• W2850035306 hasBestOaLocation W28500353061 @default.
• W2850035306 hasConcept C119060515 @default.
• W2850035306 hasConcept C121608353 @default.
• W2850035306 hasConcept C126322002 @default.
• W2850035306 hasConcept C126838900 @default.
• W2850035306 hasConcept C126894567 @default.
• W2850035306 hasConcept C143409427 @default.
• W2850035306 hasConcept C143998085 @default.
• W2850035306 hasConcept C2776235491 @default.
• W2850035306 hasConcept C2777416452 @default.
• W2850035306 hasConcept C2779013556 @default.
• W2850035306 hasConcept C2780192828 @default.
• W2850035306 hasConcept C44249647 @default.
• W2850035306 hasConcept C509974204 @default.
• W2850035306 hasConcept C71924100 @default.
• W2850035306 hasConcept C72563966 @default.
• W2850035306 hasConcept C82789193 @default.
• W2850035306 hasConceptScore W2850035306C119060515 @default.
• W2850035306 hasConceptScore W2850035306C121608353 @default.
• W2850035306 hasConceptScore W2850035306C126322002 @default.
• W2850035306 hasConceptScore W2850035306C126838900 @default.
• W2850035306 hasConceptScore W2850035306C126894567 @default.
• W2850035306 hasConceptScore W2850035306C143409427 @default.
• W2850035306 hasConceptScore W2850035306C143998085 @default.
• W2850035306 hasConceptScore W2850035306C2776235491 @default.
• W2850035306 hasConceptScore W2850035306C2777416452 @default.
• W2850035306 hasConceptScore W2850035306C2779013556 @default.
• W2850035306 hasConceptScore W2850035306C2780192828 @default.

• next